 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that GH's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Guardant Health (GH, $24.4) Stochastic Oscillator left the overbought zone on November 27, 2023

Clearbridge Investments LLC cut its stake in Guardant Health, Inc. (NASDAQ:GH  Free Report) by 27.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 1,950,659 shares of the...

Guardant Health, Inc. (NASDAQ:GH) Stake Lessened by Clearbridge Investments LLC

This indicator may be signaling GH's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Guardant Health (GH, $24.19) entered Uptrend as Momentum indicator ascends above 0 level on Nov 24, 2023

This is a Bullish indicator signaling GH's price could rise from here. Traders may explore going long the stock or buying call options...

Guardant Health (GH, $23.23) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 22, 2023

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ATAI Life Sciences (ATAI Research Report), Guardan...

Analysts Are Bullish on These Healthcare Stocks: ATAI Life Sciences (ATAI), Guardant Health (GH)

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardants Board of Directors granted restricted stock...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterdays verdict in the U.S. District Court for the District of Delaware related to...

Guardant Health to Appeal Federal District Court Verdict

This is a signal that GH's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Guardant Health (GH, $22.63) RSI Indicator left the oversold zone on November 13, 2023

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea PR...

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Guardant Health (NASDAQ:GH  Free Report) had its target price cut by Morgan Stanley from $55.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. They...

Guardant Health (NASDAQ:GH) Price Target Lowered to $50.00 at Morgan Stanley

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Watchers	4,213
52-Wk Low	$20.67
52-Wk High	$54.15

Market Cap	$2.88B
Volume (M)	1.53M
52-Wk High	$54.15
52-Wk Low	$20.67

GH Guardant Health Inc

About

Feed

News

Sentiment

Earnings

Fundamentals